Male contraception: A realistic option?

References

• Alan Guttmacher Institute. In their own right: Addressing the sexual and reproductive health needs of men worldwide. 2003
   Google Scholar
• Holden C A, McLachlan R I, Cumming R, et al. Sexual activity, fertility and contraceptive use in middle-aged and older men: Men in Australia, Telephone Survey (MATeS). Hum Reprod 2005; 20: 3429–3434
   PubMed Web of Science ®Google Scholar
• Heinemann K, Saad F, Wiesemes M, et al. Attitudes toward male fertility control: results of a multinational survey on four continents. Hum Reprod 2005; 20: 549–556
   PubMed Web of Science ®Google Scholar
• Glasier A F, Anakwe R, Everington D, et al. Would women trust their partners to use a male pill?. Hum Reprod 2000; 15: 646–649
   PubMed Web of Science ®Google Scholar
• Martin C W, Anderson R A, Cheng L, et al. Potential impact of hormonal male contraception: cross-cultural implications for development of novel preparations. Hum Reprod 2000; 15: 637–645
   PubMed Web of Science ®Google Scholar
• Weston G C, Schlipalius M L, Bhuinneain M N, et al. Will Australian men use male hormonal contraception? A survey of a postpartum population. Med J Aust 2002; 176: 208–210
   PubMed Web of Science ®Google Scholar
• World Health Organization TF. Contraceptive efficacy of testosterone-induced azoospermia in normal men. World Health Organization Task Force on Methods for the Regulation of Male Fertility. Lancet 1990; 336: 955–959
   PubMed Web of Science ®Google Scholar
• World Health Organization TF. Contraceptive efficacy of testosterone-induced azoospermia and oligozoospermia in normal men. Fertil Steril 1996; 65: 821–829
   PubMed Web of Science ®Google Scholar
• Behre H M, Baus S, Kliesch S, et al. Potential of testosterone buciclate for male contraception: endocrine differences between responders and nonresponders. J Clin Endocrinol Metab 1995; 80: 2394–2403
   PubMed Web of Science ®Google Scholar
• Nieschlag E, Hoogen H, Bolk M, et al. Clinical trial with testosterone undecanoate for male fertility control. Contraception 1978; 18: 607–614
   PubMed Web of Science ®Google Scholar
• Zhang G Y, Gu Y Q, Wang X H, et al. A pharmacokinetic study of injectable testosterone undecanoate in hypogonadal men. J Androl 1998; 19: 761–768
   PubMed Web of Science ®Google Scholar
• Zhang G Y, Gu Y Q, Wang X H, et al. A clinical trial of injectable testosterone undecanoate as a potential male contraceptive in normal Chinese men. J Clin Endocrinol Metab 1999; 84: 3642–3647
   PubMed Web of Science ®Google Scholar
• Gu Y Q, Wang X H, Xu D, et al. A multicenter contraceptive efficacy study of injectable testosterone undecanoate in healthy Chinese men. J Clin Endocrinol Metab 2003; 88: 562–568
   PubMed Web of Science ®Google Scholar
• Swerdloff R S, Wang C, Cunningham G, et al. Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men. J Clin Endocrinol Metab 2000; 85: 4500–4510
   PubMed Web of Science ®Google Scholar
• Atkinson L E. Long term experience with testosterone replacement through scrotal skin. Testosterone: Action Deficiency Substitution3rd edition, E Nieschlag, H M Behre. Cambridge University Press, Cambridge 2004; 365–388, In Nieschlag E, Behre HM, ed
   Google Scholar
• Nieschlag E, Kamischke A, Behre H M. Hormonal male contraception: The essential role of testosterone. Testosterone: Action, Deficiency, Substitution3rd edition, E Nieschlag, H M Behre, 2004; 685–714
   Google Scholar
• Büchter D, von Eckardstein S, von Eckardstein A, et al. Clinical trial of transdermal testosterone and oral levonorgestrel for male contraception. J Clin Endocrinol Metab 1999; 84: 1244–1249
   PubMed Web of Science ®Google Scholar
• Hair W M, Kitteridge K, O'Connor D B, et al. A novel male contraceptive pill-patch combination: oral desogestrel and transdermal testosterone in the suppression of spermatogenesis in normal men. J Clin Endocrinol Metab 2001; 86: 5201–5209
   PubMed Web of Science ®Google Scholar
• Meriggiola M C, Bremner W J, Costantino A, et al. An oral regimen of cyproterone acetate and testosterone undecanoate for spermatogenic suppression in men. Fertil Steril 1997; 68: 844–850
   PubMed Web of Science ®Google Scholar
• Soufir J C, Jouannet P, Marson J, et al. Reversible inhibition of sperm production and gonadotrophin secretion in men following combined oral medroxyprogesterone acetate and percutaneous testosterone treatment. Acta Endocrinol (Copenh) 1983; 102: 625–632
   PubMedGoogle Scholar
• Gonzalo I T, Swerdloff R S, Nelson A L, et al. Levonorgestrel implants (Norplant II) for male contraception clinical trials: combination with transdermal and injectable testosterone. J Clin Endocrinol Metab 2002; 87: 3562–3572
   PubMed Web of Science ®Google Scholar
• Pöllänen P, Nikkanen V, Huhtaniemi I. Combination of subcutaneous levonorgestrel implants and transdermal dihydrotestosterone gel for male hormonal contraception. Int J Androl 2001; 24: 369–380
   PubMed Web of Science ®Google Scholar
• Anawalt B D, Bebb R A, Bremner W J, et al. A lower dosage levonorgestrel and testosterone combination effectively suppresses spermatogenesis and circulating gonadotropin levels with fewer metabolic effects than higher dosage combinations. J Androl 1999; 20: 407–414
   PubMed Web of Science ®Google Scholar
• Meriggiola M C, Bremner W J, Paulsen C A, et al. A combined regimen of cyproterone acetate and testosterone enanthate as a potentially highly effective male contraceptive. J Clin Endocrinol Metab 1996; 81: 3018–3023
   PubMed Web of Science ®Google Scholar
• Wu F C, Balasubramanian R, Mulders T M, et al. Oral progestogen combined with testosterone as a potential male contraceptive: additive effects between desogestrel and testosterone enanthate in suppression of spermatogenesis, pituitary-testicular axis, and lipid metabolism. J Clin Endocrinol Metab 1999; 84: 112–122
   PubMed Web of Science ®Google Scholar
• Handelsman D J, Mackey M A, Howe C, et al. An analysis of testosterone implants for androgen replacement therapy. Clin Endocrinol (Oxf) 1997; 47: 311–316
   PubMed Web of Science ®Google Scholar
• Jockenhövel F, Vogel E, Kreutzer M, et al. Pharmacokinetics and pharmacodynamics of subcutaneous testosterone implants in hypogonadal men. Clin Endocrinol (Oxf) 1996; 45: 61–71
   PubMed Web of Science ®Google Scholar
• McLachlan R I, McDonald J, Rushford D, et al. Efficacy and acceptability of testosterone implants, alone or in combination with a 5alpha-reductase inhibitor, for male hormonal contraception. Contraception 2000; 62: 73–78
   PubMed Web of Science ®Google Scholar
• von Eckardstein S, Noe G, Brache V, et al. A clinical trial of 7 alpha-methyl-19-nortestosterone implants for possible use as a long-acting contraceptive for men. J Clin Endocrinol Metab 2003; 88: 5232–5239
   PubMed Web of Science ®Google Scholar
• Suvisaari J, Moo-Young A, Juhakoski A, et al. Pharmacokinetics of 7 alpha-methyl-19-nortestosterone (MENT) delivery using subdermal implants in healthy men. Contraception 1999; 60: 299–303
   PubMed Web of Science ®Google Scholar
• Swerdloff R S, Bagatell C J, Wang C, et al. Suppression of spermatogenesis in man induced by Nal-Glu gonadotropin releasing hormone antagonist and testosterone enanthate (TE) is maintained by TE alone. J Clin Endocrinol Metab 1998; 83: 3527–3533
   PubMed Web of Science ®Google Scholar
• Behre H M, Kliesch S, Lemcke B, et al. Suppression of spermatogenesis to azoospermia by combined administration of GnRH antagonist and 19-nortestosterone cannot be maintained by this non-aromatizable androgen alone. Hum Reprod 2001; 16: 2570–2577
   PubMed Web of Science ®Google Scholar
• Matthiesson K L, Amory J K, Berger R, et al. Novel male hormonal contraceptive combinations: the hormonal and spermatogenic effects of testosterone and levonorgestrel combined with a 5alpha-reductase inhibitor or gonadotropin-releasing hormone antagonist. J Clin Endocrinol Metab 2005; 90: 91–97
   PubMed Web of Science ®Google Scholar
• Grimes D A, Gallo M F, Grigorieva V, et al. Steroid hormones for contraception in men: systematic review of randomized controlled trials. Contraception 2005; 71: 89–94
   PubMed Web of Science ®Google Scholar
• Begg C, Cho M, Eastwood S, et al. Improving the quality of reporting of randomized controlled trials. The CONSORT statement. J Am Med Assoc 1996; 276: 637–639
   PubMed Web of Science ®Google Scholar
• Moher D, Schulz K F, Altman D. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. J Am Med Assoc 2001; 285: 1987–1991
   PubMed Web of Science ®Google Scholar
• Nieschlag E, Zitzmann M, Kamischke A. Use of progestins in male contraception. Steroids 2003; 68: 965–972
   PubMed Web of Science ®Google Scholar
• Barfield A, Melo J, Coutinho E, et al. Pregnancies associated with sperm concentrations below 10 million/ml in clinical studies of a potential male contraceptive method, monthly depot medroxyprogesterone acetate and testosterone esters. Contraception 1979; 20: 121–127
   PubMed Web of Science ®Google Scholar
• Schürmeyer T, Knuth U A, Belkien L, et al. Reversible azoospermia induced by the anabolic steroid 19-nortestosterone. Lancet 1984; i: 417–420
   Google Scholar
• Knuth U A, Yeung C H, Nieschlag E. Combination of 19-nortestosterone-hexyloxyphenylpropionate (Anadur) and depot-medroxyprogesterone-acetate (Clinovir) for male contraception. Fertil Steril 1989; 51: 1011–1018
   PubMed Web of Science ®Google Scholar
• World Health Organization TF. Comparison of two androgens plus depot-medroxyprogesterone acetate for suppression to azoospermia in indonesian men. World Health Organization. Task force on methods for the regulation of male fertility. Fertil Steril 1993; 60: 1062–1068
   PubMed Web of Science ®Google Scholar
• Turner L, Conway A J, Jimenez M, et al. Contraceptive efficacy of a depot progestin and androgen combination in men. J Clin Endocrinol Metab 2003; 88: 4659–4667
   PubMed Web of Science ®Google Scholar
• Fogh M, Corker C S, McLean H, et al. Clinical trial with levo-norgestrel and testosterone oenanthate for male fertility control. Acta Endocrinol (Copenh) 1980; 95: 251–257
   PubMedGoogle Scholar
• Bebb R A, Anawalt B D, Christensen R B, et al. Combined administration of levonorgestrel and testosterone induces more rapid and effective suppression of spermatogenesis than testosterone alone: a promising male contraceptive approach. J Clin Endocrinol Metab 1996; 81: 757–762
   PubMed Web of Science ®Google Scholar
• Kamischke A, Plöger D, Venherm S, et al. Intramuscular testosterone undecanoate with or without oral levonorgestrel: a randomized placebo-controlled feasibility study for male contraception. Clin Endocrinol (Oxf) 2000; 53: 43–52
   PubMed Web of Science ®Google Scholar
• Wang C, Wang X H, Nelson A L, et al. Levonorgestrel implants enhanced the suppression of spermatogenesis by testosterone implants: comparison between Chinese and non-Chinese nen*. J Clin Endocrinol Metab 2005, *[Epub ahead of print]
   Web of Science ®Google Scholar
• Guerin J F, Rollet J. Inhibition of spermatogenesis in men using various combinations of oral progestagens and percutaneous or oral androgens. Int J Androl 1988; 11: 187–199
   PubMed Web of Science ®Google Scholar
• Kamischke A, Diebacker J, Nieschlag E. Potential of norethisterone enanthate for male contraception: pharmacokinetics and suppression of pituitary and gonadal function. Clin Endocrinol (Oxf) 2000; 53: 351–358
   PubMed Web of Science ®Google Scholar
• Kamischke A, Heuermann T, Kruger K, et al. An effective hormonal male contraceptive using testosterone undecanoate with oral or injectable norethisterone preparations. J Clin Endocrinol Metab 2002; 87: 530–539
   PubMed Web of Science ®Google Scholar
• Meriggiola M C, Costantino A, Saad F, et al. Norethisterone enanthate plus testosterone undecanoate for male contraception: effects of various injection intervals on spermatogenesis, reproductive hormones, testis, and prostate. J Clin Endocrinol Metab 2005; 90: 2005–2014
   PubMed Web of Science ®Google Scholar
• Kamischke A, Venherm S, Plöger D, et al. Intramuscular testosterone undecanoate and norethisterone enanthate in a clinical trial for male contraception. J Clin Endocrinol Metab 2001; 86: 303–309
   PubMed Web of Science ®Google Scholar
• World Health Organization. Controlled trials register NET-EN plus TU as a male contraceptive (WHO-HRP ID A25165), (accessed 2005-11–29). http://www.who.int/reproductive-health/rhl/a25165.html
   Google Scholar
• Meriggiola M C, Bremner W J, Costantino A, et al. Low dose of cyproterone acetate and testosterone enanthate for contraception in men. Hum Reprod 1998; 13: 1225–1229
   PubMed Web of Science ®Google Scholar
• Meriggiola M C, Costantino A, Bremner W J, et al. Higher testosterone dose impairs sperm suppression induced by a combined androgen-progestin regimen. J Androl 2002; 23: 684–690
   PubMed Web of Science ®Google Scholar
• Meriggiola M C, Costantino A, Cerpolini S, et al. Testosterone undecanoate maintains spermatogenic suppression induced by cyproterone acetate plus testosterone undecanoate in normal men. J Clin Endocrinol Metab 2003; 88: 5818–5826
   PubMed Web of Science ®Google Scholar
• Sitruk-Ware R. New progestagens for contraceptive use. Hum Reprod Update 2006; 12: 169–178
   PubMed Web of Science ®Google Scholar
• Meriggiola M C, Bremner W J, Costantino A, et al. Twenty-one day administration of dienogest reversibly suppresses gonadotropins and testosterone in normal men. J Clin Endocrinol Metab 2002; 87: 2107–2113
   PubMed Web of Science ®Google Scholar
• Anawalt B D, Herbst K L, Matsumoto A M, et al. Desogestrel plus testosterone effectively suppresses spermatogenesis but also causes modest weight gain and high-density lipoprotein suppression. Fertil Steril 2000; 74: 707–714
   PubMed Web of Science ®Google Scholar
• Martin C W, Riley S C, Everington D, et al. Dose-finding study of oral desogestrel with testosterone pellets for suppression of the pituitary-testicular axis in normal men. Hum Reprod 2000; 15: 1515–1524
   PubMed Web of Science ®Google Scholar
• Anderson R A, Kinniburgh D, Baird D T. Suppression of spermatogenesis by etonogestrel implants with depot testosterone: potential for long-acting male contraception. J Clin Endocrinol Metab 2002; 87: 3640–3649
   PubMed Web of Science ®Google Scholar
• Brady B M, Walton M, Hollow N, et al. Depot testosterone with etonogestrel implants result in induction of azoospermia in all men for long-term contraception. Hum Reprod 2004; 19: 2658–2667
   PubMed Web of Science ®Google Scholar
• Hoesl C E, Saad F, Poppel M, et al. Reversible, non-barrier male contraception: status and prospects. Eur Urol 2005; 48: 712–722, discussion 722–3
   PubMed Web of Science ®Google Scholar
• Nieschlag E, Henke A. Hopes for male contraception. Lancet 2005; 365: 554–556
   PubMed Web of Science ®Google Scholar